Severe hypertriglyceridemia following sirolimus use in an infant

Hannah Clark; Rachael Schulte; Anita N Haggstrom

doi:10.1111/pde.14853

Severe hypertriglyceridemia following sirolimus use in an infant

Pediatr Dermatol. 2021 Nov;38(6):1581-1582. doi: 10.1111/pde.14853. Epub 2021 Nov 8.

Authors

Hannah Clark¹, Rachael Schulte², Anita N Haggstrom³

Affiliations

¹ Indiana University School of Medicine, Indianapolis, Indiana, USA.
² Departments of Pediatrics and Dermatology, Indiana University, Indianapolis, Indiana, USA.
³ Division of Pediatric Hematology/Oncology, Indiana University, Indianapolis, Indiana, USA.

PMID: 34749436
DOI: 10.1111/pde.14853

Abstract

Inhibitors of mammalian target of rapamycin function to downregulate cell growth and proliferation and have off-label use in pediatrics for vascular malformations. Hypertriglyceridemia is a known side effect of mammalian target of rapamycin (mTOR) inhibitors. Further studies to better understand the incidence and treatment of hypertriglyceridemia in infants and neonates are warranted.

Keywords: arteriovenous malformation; triglycerides; vascular malformation.

MeSH terms

Child
Humans
Hypertriglyceridemia* / chemically induced
Sirolimus* / adverse effects

Substances

Sirolimus